Science - USA (2022-01-14)

SCIENCEscience.org 14 JANUARY 2022¥VOL 375 ISSUE 6577 185

ABC

D

E

F

IJK

G

16-1828-

30 4254

1

10

100

1,000

10,000

100,000

RBD antibody titer

---

-- ++

0/260/2626/26

p < 0.0001

SARS-CoV-2 infection

(Wuhan Hu-1)

Vaccination

26/26

• 
  

• 
  

p < 0.0001

16-1828-30

4254

-- ++

+++

22/2422/2425/25

p = 0.0141

p < 0.0001

25/25

+

+

Weeks

1

10

100

1000

SFC per 10

6 PBMC

• 
  

14/23

21/23 22/24

24/24

p = 0.0005

p = 0.0006

• 
  
  
  
  • 
    
    
    
    • 
      
    
    
    
    
  
  
  
  

p = 0.0159

p = 0.0294

SARS-CoV-2 infection

(Wuhan Hu-1) - +

Vaccination- + ++ - + ++

p = 0.0032

11/23

19/24

-+-+-+-+-+

100

1,000

10,000

100,000

1,000,000

Neutralization (IC50)

Wuhan Hu-1 B.1.1.7

SARS-CoV-2 infection

(Wuhan Hu-1)

B.1.351 P. 1

fold

decrease

2.4 5.9 7.9

3.8 8.7 10.6

B.1.617.2

27.7

23.0

0.01

0.1

1

10

100

% S1 specific IgG+ ASC

SARS-CoV-2 infection

(Wuhan Hu-1)

Vaccination

• 
  


• 
  
  
  
  • 
    
    
    
    • 
      
    
    
    
    
  
  
  
  

+

+

• 
  
  
  
  • 
    
  
  
  
  

0/5

24/26

10/12 24/24

• 
  
  
  
  • 
    
  
  
  
  

++++

13/13 9/9

p = 0.0065

p < 0.0001

Wuhan Hu-1

N5

01Y

, E484K, K417N

0.01

0.1

1

10

100

% S1 specific IgG+ ASC

n = 8

Wu

han

Hu-1

N501Y, E484K, K417N

0.01

0.1

1

10

100

% S1 specific IgG+ ASC

n = 12

0.01

0.1

1

10

100

% S1 specific IgG+ ASC

p = 0.0002

n = 13 n = 9

• 
  
  
  
  • 
    
    
    
    • 
      
      
      
      • VVVaccination
      
      
      
      
    
    
    
    
  
  
  
  

SARS-CoV-2 infection

(Wuhan Hu-1)

+ ++ + ++

1,000 10,000 100,000

100

1,000

10,000

100,000

1,000,000

Roche S1 RBD titer

Neutralization (IC50)

Wuhan Hu-1

p < 0.0001

r = 0.621

000 1,000 10,000 100,000

100

1,000

10,000

100,000

1,000,000

Roche S1 RBD titer

Neutralization (IC50)

B.1.1.7

p < 0.0001

r = 0.732

000 1,000 10,000 100,000

100

1,000

10,000

100,000

1,000,000

Roche S1 RBD titer

Neutralization (IC50)

B.1.351

p < 0.0001

r = 0.602

000 1,000 10,000 100,000

100

1,000

10,000

100,000

1,000,000

Roche S1 RBD titer

Neutralization (IC50)

P. 1

p < 0.0001

r = 0.637

1,000 10,000 100,000

100

1,000

10,000

100,000

1,000,000

Roche S1 RBD titer

Neutralization (IC50)

B.1.617.2

p = 0.0004

r = 0.525

200,000 400,000 600,000

100

1,000

10,000

100,000

1,000,000

Wuhan Hu-1 RBD titer

Neutralization (IC50)

p < 0.0001

r = 0.570

200,000 400,000 600,000

100

1,000

10,000

100,000

1,000,000

B.1.351 RBD titer

Neutralization (IC50)

p = 0.0003

r = 0.516

,000 200,000 400,000 600,000

100

1,000

10,000

100,000

1,000,000

P.1 RBD titer

Neutralization (IC50)

p < 0.0001

r = 0.554

, 000

1

Neutralization (I

C^50

)

200,000 400,000 600,000

100

1,000

10,000

100,000

1,000,000

B.1.1.7 RBD titer

Neutralization (IC50)

p < 0.0001

r = 0.619

200,000 400,000 600,000

100

1,000

10,000

100,000

1,000,000

B.1.617.2 RBD titer

Neutralization (IC50)

p = 0.0034

r = 0.433

H

16-1828-30

42 54

1

10

100

1,000

N relative antibody index

SARS-CoV-2 infection

(Wuhan Hu-1)

Vaccination

---

• 
  
  
  
  • ++
  
  
  
  

0/260/240/26

• 
  

• 
  

2/26

16-1828-30

42 54

-- ++

++ +

22/2423/2523/25

+

+

21/25

p = 0.0003

p < 0.0001

p < 0.0001

Weeks

100

1,000

10,000

100,000

1,000,000

Neutralization (IC50)

16-fold 123-fold

100

1,000

10,000

100,000

1,000,000

Neutralization (IC50)

27-fold 6-fold

3-fold589-fold

52-fold 23-fold

445-fold

65-fold 3-fold

1765-fold

63-fold 0.8-fold

VVVaccination - + - - -

Wuhan Hu- (^1) B.1.1. (^7) B.1.35 1 PPP. 1
++ + ++ + ++ + ++
48-fold39-fold
21-fold 3-fold

• 
  

B.1.617. 2

+ ++

n= 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20

n = 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24

p < 0.0001p < 0.0001 p = 0.0122p < 0.0001 p = 0.0039p < 0.0001 p = 0.500p < 0.0001 p = 0.0059p < 0.0001

p < 0.0001p < 0.0001 p < 0.0001p < 0.0001 p < 0.0001p = 0.0005 p < 0.0001p = 0.5803 p < 0.0001p = 0.0002

Wuhan Hu-1

0.01

0.1

1

10

100

% S1 specific IgG+ ASC

T19R, G

142D, del

156-157

,

R^15

8G, L452R,

T478

K,

D614G, P

681R

n = 21 22

RESEARCH | RESEARCH ARTICLES